2014 Q2/Global Life Sciences
Rank | Chg | Organisation name | Overall |
|
---|---|---|---|---|
|
||||
1 | +1 |
Cytogen
|
8.2 | |
|
||||
2 | +77 |
Biogen Idec
|
7.9 | |
|
||||
3 | +5 |
Taisho Pharmaceutical
|
7.2 | |
|
||||
4 | -1 |
Kyowa Hakko Kirin UK
|
7.2 | |
|
||||
5 | +1 |
Biotecnol
|
7.1 | |
|
||||
6 | +9 |
Vectura
|
7.1 | |
|
||||
7 | -2 |
Kyorin Holdings
|
7.0 | |
|
||||
8 | -4 |
Galenica AG
|
6.9 | |
|
||||
9 | +2 |
Kaken Pharmaceutical
|
6.7 | |
|
||||
10 | +8 |
Otsuka Pharmaceuticals Europe
|
6.6 | |
|
||||
11 | -2 |
EISAI UK
|
6.6 | |
|
||||
12 | -2 |
Wockhardt
|
6.6 | |
|
||||
13 | +0 |
Actelion UK
|
6.4 | |
|
||||
14 | -7 |
Questcor
|
6.4 | |
|
||||
15 | +2 |
Advaxis
|
6.3 | |
|
||||
16 | +9 |
Otsuka Pharmaceuticals
|
6.2 | |
|
||||
17 | -1 |
EISAI
|
6.0 | |
|
||||
18 | +3 |
Meda Pharmaceuticals
|
5.8 | |
|
||||
19 | -7 |
Yakult UK
|
5.8 | |
|
||||
20 | +2 |
Genmab
|
5.7 | |
|
||||
21 | +30 |
MorphoSys
|
5.7 | |
|
||||
22 | -8 |
Servier UK
|
5.6 | |
|
||||
23 | +1 |
Actelion
|
5.5 | |
|
||||
24 | -4 |
Genzyme UK
|
5.4 | |
|
||||
25 | +32 |
Debiopharm
|
5.3 | |
|
||||
26 | +40 |
Nippon Chemiphar
|
5.3 | |
|
||||
27 | +14 |
Covence
|
5.3 | |
|
||||
28 | +5 |
Novartis UK
|
5.3 | |
|
||||
29 | +0 |
Zandu
|
5.2 | |
|
||||
30 | -1 |
Dainippon Sumitomo
|
5.2 | |
|
||||
31 | +37 |
Anavex Life Sciences Corp
|
5.2 | |
|
||||
32 | -1 |
QLT
|
5.2 | |
|
||||
33 | -5 |
Recordati
|
5.1 | |
|
||||
34 | -7 |
Valeant Pharmaceuticals
|
5.1 | |
|
||||
35 | +20 |
KRKA
|
5.0 | |
|
||||
36 | +8 |
Bavarian Nordic
|
5.0 | |
|
||||
37 | -7 |
Dusa Pharmaceuticals
|
5.0 | |
|
||||
38 | +21 |
Alkermes
|
4.9 | |
|
||||
39 | +1 |
Laboratoires Thea
|
4.9 | |
|
||||
40 | +6 |
Apotex
|
4.9 | |
|
||||
41 | +110 |
Forest
|
4.9 | |
|
||||
42 | +23 |
Kissei
|
4.9 | |
|
||||
43 | +0 |
Boehringer Ingelheim
|
4.9 | |
|
||||
44 | +8 |
Mylan
|
4.9 | |
|
||||
45 | -11 |
Santen
|
4.8 | |
|
||||
46 | +96 |
Therabel
|
4.8 | |
|
||||
47 | +0 |
CSL Behring UK
|
4.8 | |
|
||||
48 | +0 |
Stallergenes UK
|
4.8 | |
|
||||
49 | -11 |
Sanofi UK
|
4.8 | |
|
||||
50 | +0 |
Galderma
|
4.8 | |
|
Changes in rank are compared to 2014 Q1/Global Life Sciences. Since then, 6 sites entered the survey, 1 site left the survey and 52 sites could not be included in the rankings (3 fewer since last time). Build your own. Report statistics.
Priorities Summary
The priorities for this organization are not currently available to view.
Contact Us